Biocryst Pharmaceuticals Inc. (BCRX) Is Not Likely To Be The Same Tomorrow

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Recently, Yahoo Finance discussed the stock, revealing that BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

Biocryst Pharmaceuticals Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $5.51 and fluctuated between $5.52 as its day high and $5.02 as its day low. The current market capitalization of Biocryst Pharmaceuticals Inc. is $1.13B. A total of 2.48 million shares were traded on the day, compared to an average of 3.87M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, BCRX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 20 BUYs and 4 SELLs from insiders. Insiders purchased 207,607 shares during that period but sold 48,866.

In the most recent transaction, SANDERS MACHELLE sold 4,000 shares of BCRX for 7.98 per share on Jun 15. After the transaction, the Director now owns 25,611 company shares. In a previous transaction on Jun 14, Hutson Nancy J sold 12,866 shares at 8.04 per share. BCRX shares that Director owns now total 81,818.

Among the insiders who sold shares, Thackray Helen M. disposed of 7,000 shares on Apr 03 at a per-share price of $8.29. This resulted in the Chief R&D Officer holding 207,275 shares of BCRX after the transaction.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for BCRX in the last 3 months, the mean price target is $13.82 with high estimates of $30.00 and low estimates of $6.00. In terms of 52-week highs and lows, BCRX has a high of $10.74 and a low of $4.82.

As of this writing, BCRX has an earnings estimate of -$0.24 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.14 per share and a lower estimate of -$0.38. The company reported an EPS of -$0.4 in the last quarter, which was -73.90% lower than expectations of -$0.23.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. BCRX’s latest balance sheet shows that the firm has $507.60M in Cash & Short Term Investments as of fiscal 2021. There were $593.24M in debt and $103.72M in liabilities at the time. Its Book Value Per Share was -$2.17, while its Total Shareholder’s Equity was -$106.99M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCRX is Buy with a score of 4.50.

Most Popular

Related Posts